Your browser is no longer supported. Please, upgrade your browser.
PTGX [NASD]
Protagonist Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.41 Insider Own1.20% Shs Outstand47.99M Perf Week-10.84%
Market Cap1.53B Forward P/E- EPS next Y-3.13 Insider Trans-2.42% Shs Float47.17M Perf Month-6.16%
Income-107.50M PEG- EPS next Q-1.01 Inst Own- Short Float7.97% Perf Quarter-37.75%
Sales24.40M P/S62.89 EPS this Y35.50% Inst Trans-3.05% Short Ratio1.91 Perf Half Y-11.25%
Book/sh6.87 P/B4.50 EPS next Y8.30% ROA-30.70% Target Price59.00 Perf Year33.49%
Cash/sh6.34 P/C4.88 EPS next 5Y- ROE-35.10% 52W Range12.80 - 50.54 Perf YTD53.42%
Dividend- P/FCF- EPS past 5Y-13.60% ROI-23.80% 52W High-38.80% Beta2.19
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low141.64% ATR1.96
Employees116 Current Ratio8.40 Sales Q/Q-21.40% Oper. Margin- RSI (14)40.50 Volatility7.50% 5.75%
OptionableYes Debt/Eq0.00 EPS Q/Q-239.30% Profit Margin- Rel Volume0.37 Prev Close33.62
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.97M Price30.93
Recom1.60 SMA20-11.08% SMA506.71% SMA200-11.43% Volume730,156 Change-8.00%
Oct-12-21Upgrade JP Morgan Neutral → Overweight $49 → $55
Oct-11-21Upgrade Northland Capital Market Perform → Outperform $40
Sep-20-21Downgrade JP Morgan Overweight → Neutral $60 → $49
May-24-21Initiated Northland Capital Outperform $42
May-24-21Initiated JMP Securities Mkt Outperform $48
Jan-06-21Initiated JP Morgan Overweight
Dec-16-20Initiated Piper Sandler Overweight $53
Sep-18-20Reiterated H.C. Wainwright Buy $28 → $33
Jul-15-20Initiated Jefferies Buy $27
May-18-20Reiterated H.C. Wainwright Buy $23 → $28
Jul-08-19Initiated H.C. Wainwright Buy $23
May-09-19Upgrade Stifel Hold → Buy $11 → $17
Dec-06-18Initiated Nomura Buy $13
Jan-29-18Initiated Stifel Buy $32
Jul-21-17Initiated BTIG Research Buy $36
Nov-15-21 07:00AM  
Nov-11-21 07:00AM  
Nov-08-21 08:12AM  
Nov-04-21 07:00AM  
Nov-03-21 06:25PM  
04:05PM  
Oct-27-21 03:03PM  
Oct-26-21 07:00AM  
Oct-18-21 06:09AM  
Oct-14-21 09:27AM  
Oct-13-21 08:25PM  
Oct-12-21 07:00AM  
05:01AM  
Oct-11-21 04:07PM  
12:04PM  
08:11AM  
07:00AM  
Oct-04-21 07:00AM  
Sep-23-21 11:00AM  
Sep-22-21 09:11PM  
11:40AM  
07:59AM  
Sep-21-21 02:58PM  
Sep-20-21 04:14PM  
Sep-17-21 04:06PM  
03:10PM  
02:48PM  
12:12PM  
07:00AM  
Sep-15-21 05:05PM  
Sep-07-21 07:00AM  
Aug-10-21 08:05AM  
01:53AM  
Aug-04-21 06:45PM  
04:05PM  
Jul-29-21 03:05PM  
Jul-28-21 04:05PM  
Jul-21-21 04:32AM  
Jul-06-21 07:17AM  
Jun-30-21 04:27PM  
Jun-18-21 04:05PM  
Jun-17-21 08:57AM  
Jun-16-21 06:53AM  
Jun-15-21 09:07PM  
Jun-14-21 05:00PM  
09:38AM  
Jun-11-21 02:09PM  
07:00AM  
Jun-07-21 07:06AM  
Jun-03-21 07:00AM  
May-24-21 07:00AM  
May-21-21 10:59AM  
May-12-21 11:14AM  
May-04-21 06:20PM  
04:01PM  
May-03-21 05:47PM  
Apr-27-21 07:00AM  
Apr-24-21 05:08PM  
Apr-07-21 08:47AM  
Mar-22-21 04:01PM  
08:03AM  
Mar-10-21 05:55PM  
04:01PM  
01:30PM  
Mar-03-21 07:00AM  
Mar-02-21 12:30PM  
07:00AM  
Feb-26-21 06:19PM  
Feb-16-21 07:00AM  
Jan-29-21 06:22PM  
Jan-07-21 04:18AM  
Jan-04-21 07:00AM  
Dec-29-20 08:53AM  
Dec-17-20 09:36AM  
Dec-16-20 07:30AM  
Dec-15-20 04:30PM  
Dec-13-20 08:37AM  
Dec-10-20 11:10PM  
07:30AM  
Dec-07-20 10:00AM  
Dec-06-20 02:45PM  
Dec-02-20 07:00AM  
Dec-01-20 04:30PM  
Nov-30-20 07:00AM  
Nov-25-20 07:00AM  
Nov-11-20 04:30PM  
Nov-04-20 06:45PM  
04:54PM  
10:20AM  
Oct-30-20 06:27PM  
Oct-29-20 04:30PM  
Oct-28-20 12:32PM  
Oct-21-20 07:00AM  
Oct-09-20 11:53AM  
Sep-17-20 04:30PM  
Sep-15-20 04:48PM  
Sep-10-20 04:30PM  
Sep-02-20 04:30PM  
Aug-25-20 10:54AM  
Aug-13-20 04:30PM  
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATEL DINESH V PH DPresident and CEOSep 21Option Exercise4.2140,000168,400492,158Sep 21 09:45 PM
Liu David YChief Scientific OfficerAug 17Option Exercise0.8710,0008,70073,033Aug 19 05:49 PM
Liu David YChief Scientific OfficerAug 17Sale47.5614,779702,88958,254Aug 19 05:49 PM
Noonberg Sarah B.DirectorFeb 11Sale25.093,70092,8330Feb 12 06:36 PM
Noonberg Sarah B.DirectorFeb 10Sale25.474,700119,7220Feb 12 06:36 PM
PATEL DINESH V PH DPresident and CEOJan 19Option Exercise4.2113,00054,730450,990Jan 20 08:20 PM
PATEL DINESH V PH DPresident and CEOJan 19Sale24.6024,846611,105426,144Jan 20 08:20 PM